Abstract
Abstract
Background
Esophageal cancer is one of the most aggressive malignancies, and is associated with multiple genetic mutations. At present, the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation has been observed in esophageal cancer and is associated with poor prognosis. This study aimed to investigate the protein expression of BRAF in esophageal cancer and determine its effect on patient outcomes.
Methods
We used immunohistochemistry to detect the expression of BRAF via tissue microarrays in esophageal cancer samples, the Kaplan–Meier method to perform survival analysis, and the Cox proportional hazards regression model to explore the risk factors of esophageal cancer. The role of BRAF in the proliferation, invasion, and metastasis of esophageal cancer was studied by clone formation, scratch test, Transwell invasion and migration test. The tumor-bearing model of BRAF inhibitor was established using TE-1 cells, and corresponding negative control was set up to observe the growth rate of the two models.
Results
The results revealed that BRAF overexpression was significantly correlated with Ki67 (P < 0.05). Survival analysis showed that BRAF overexpression contributed to a shorter overall survival (P = 0.014) in patients with esophageal cancer. Univariate and multivariate regression analyses demonstrated that BRAF was a prognostic factor for poor esophageal cancer outcomes (P < 0.05). Small interfering RNA knockdown of BRAF significantly reduced the cell clone formation rate compared to the control group. Transwell assay analysis showed that the migration and invasion of cells in the experimental group were significantly inhibited relative to the control group, and the inhibition rates of the small interfering RNA group were 67% and 60%, respectively. In the scratch test, the wound healing ability of the BRAF knockdown group was significantly weaker than that of the control group. There were significant differences in tumor growth volume and weight between the two groups in nude mice.
Conclusion
BRAF overexpression may serve as an effective predictive factor for poor prognosis.
Funder
Natural Science Foundation of Xinjiang Province
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference23 articles.
1. Ervik M, Soerjomataram I, Ferlay J. GLOBOCAN 2012 estimated cancer incidence, mortality and prevalence worldwide in 2012. Gut. 2015;64(3):381–7.
2. Kollarova H, Machova L, Horakova D, Janoutova G, Janout V. Epidemiology of esophageal cancer—an overview article. Biomed Pap Med Faculty Palacky Univ Olomouc. 2007;151:1.
3. Jiao WP, Zhang JY, Wei YY, Feng JH, Ma M, Zhao HZ, Wang LH, Jiao WJ. MiR-139-5p regulates VEGFR and downstream signaling pathways to inhibit the development of esophageal cancer. Digest Liver Dis. 2019;51(1):149–56.
4. Han W, Lo HWJCL. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012;318(2):124–34.
5. Santarpia L, Lippman SM, El-Naggar AKJEOTT. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–19.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献